Chronic Pancreatitis Market

 Market Overview:

The 7 major chronic pancreatitis markets reached a value of US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.49% during 2024-2034.

The chronic pancreatitis market has been comprehensively analyzed in IMARC's new report titled "Chronic Pancreatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic pancreatitis refers to long-term inflammation of the pancreas, a gland located behind the stomach. It is often characterized by the destruction and scarring of pancreatic tissue. Over time, this condition can impair the normal functioning of the pancreas, affecting its ability to produce digestive enzymes and hormones. The common symptoms associated with the ailment include pain in the upper abdomen, diarrhea, fatty, loose and pale stools, nausea, vomiting, shortness of breath, unexplained weight loss, excessive thirst, fatigue, etc. In severe cases, individuals suffering from this disease may also experience a yellowish discoloration in the eyes and skin, pancreatic fluids in the abdomen, internal bleeding, intestinal blockage, etc. The diagnosis of chronic pancreatitis typically involves a review of the patient's underlying symptoms, medical history, and imaging studies. Numerous procedures, including X-rays, ultrasounds, computed tomography scans, magnetic resonance imaging, etc., are adopted to identify abnormalities in the abdomen or check for any signs of inflammation in patients. The healthcare provider may also perform an endoscopy to directly visualize the condition of the pancreas and confirm a diagnosis.

The increasing incidence of prolonged and excessive alcohol intake, which can lead to inflammation and damage to the pancreas, is primarily driving the chronic pancreatitis market. Apart from this, the rising prevalence of gallstones, which can cause blockages in the pancreatic duct and prevent the normal flow of digestive enzymes, is also augmenting the market growth. Moreover, the widespread utilization of nonsteroidal anti-inflammatory drugs, opioids, analgesics, etc., for treating the disease, since they help in reducing the pain associated with the condition, is further creating a positive outlook for the market. Besides this, the inflating application of enzyme replacement therapy to significantly improve digestion and nutrient absorption in patients is also propelling the market growth. Furthermore, the escalating utilization of endoscopic retrograde cholangiopancreatography techniques that combine endoscopy and fluoroscopy to diagnose and treat conditions of the pancreatic duct is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal shock wave lithotripsy, a non-invasive procedure that uses shock waves to break down gallstones or pancreatic stones, thereby normalizing the functions of the pancreas, is expected to drive the chronic pancreatitis market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the chronic pancreatitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic pancreatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic pancreatitis market in any manner.

Key Highlights:

• The prevalence of chronic pancreatitis is 45.52 per 100,000 people, with men and the elderly having greater rates.
• The prevalence is modest before the age of 35, but rises to 100-120 per 100,000 in middle-aged and older men.
• The incidence of chronic pancreatitis is estimated to range between 4.4-14 per 100,000 persons.
• In most studies, 60-80% of chronic pancreatitis patients are male, and population studies demonstrate a higher incidence and prevalence of chronic pancreatitis in men than in women.
• Alcohol is the most common cause of chronic pancreatitis in the age group of 35-54 years.

Drugs:

NI-03 (camostat mesilate) is an orally administered serine protease inhibitor that lowers pancreatic enzyme activity and has been widely utilized for the treatment of chronic pancreatitis-related discomfort.

MS1819 SD, a recombinant lipase produced from the yeast Yarrowia Lipolytica, is being developed to treat exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis and cystic fibrosis (CF).  Early Phase Ib data in EPI patients treated with MS1819 revealed a satisfactory safety profile as well as promising early effectiveness signs.

CM-6018 is an ORAI1 inhibitors, immunosuppressant drug developed by CalciMedica. It is a small molecule drug used for the treatment of chronic pancreatitis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic pancreatitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic pancreatitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic pancreatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic pancreatitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic pancreatitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic pancreatitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic pancreatitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic pancreatitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic pancreatitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic pancreatitis across the seven major markets?
• What is the size of the chronic pancreatitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic pancreatitis?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Pancreatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic pancreatitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic pancreatitis market?
• What are the key regulatory events related to the chronic pancreatitis market?
• What is the structure of clinical trial landscape by status related to the chronic pancreatitis market?
• What is the structure of clinical trial landscape by phase related to the chronic pancreatitis market?
• What is the structure of clinical trial landscape by route of administration related to the chronic pancreatitis market?